CN109457024A - Shr gene polymorphism fluorescent PCR solubility curve detection kit and application - Google Patents

Shr gene polymorphism fluorescent PCR solubility curve detection kit and application Download PDF

Info

Publication number
CN109457024A
CN109457024A CN201810245896.8A CN201810245896A CN109457024A CN 109457024 A CN109457024 A CN 109457024A CN 201810245896 A CN201810245896 A CN 201810245896A CN 109457024 A CN109457024 A CN 109457024A
Authority
CN
China
Prior art keywords
primer
probe
pcr reaction
sequence
reaction solution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201810245896.8A
Other languages
Chinese (zh)
Inventor
倪晓龙
李亚波
李春凤
欧阳云
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zhongfu Health Technology (Hangzhou) Co.,Ltd.
Original Assignee
Hangzhou Thailand Biotechnology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hangzhou Thailand Biotechnology Co Ltd filed Critical Hangzhou Thailand Biotechnology Co Ltd
Priority to CN201810245896.8A priority Critical patent/CN109457024A/en
Publication of CN109457024A publication Critical patent/CN109457024A/en
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6844Nucleic acid amplification reactions
    • C12Q1/686Polymerase chain reaction [PCR]
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/106Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12QMEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00Oligonucleotides characterized by their use
    • C12Q2600/156Polymorphic or mutational markers

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pathology (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

The present invention relates to a kind of shr gene polymorphism fluorescent PCR solubility curve detection kits, and its application and a kind of multiplex PCR melting curve detection method for detecting hypertension medication gene.The kit mainly includes primer combination, probe combinations, and the PCR reaction reagent such as thermal starting polymerase, PCR reaction buffer, dNTPs, the 7 kinds of genetic polymorphism detections of correlation of medication containing hypertension, it is CYP2D6*10, CYP2C9*3, ADRB1 (1165G > C), AGTR1 (1166A > C), CYP3A5*3, NPPA (T2238C), ACE (I/D) respectively, PCR amplification and liquation are carried out by 3 reaction solutions, the case where judging 7 gene-correlation polymorphisms, to instruct the personalized application of 5 major class drug of Clinical Hypertension.The present invention is easily accomplished detection process by 3 reaction tubes, while detection process is not necessarily to nucleic acid extraction process, simplifies operating procedure, and interpretation method is simple.

Description

Shr gene polymorphism fluorescent PCR solubility curve detection kit and application
(1) technical field
The present invention relates to a kind of shr gene polymorphism fluorescent PCR solubility curve detection kits, and its application, and A kind of multiplex PCR melting curve detection method detecting hypertension medication gene.
(2) background technique
Hypertension is higher as a kind of Chronic Non-Communicable Diseases and China's illness rate, disability rate is higher and disease is negative Carry on a shoulder pole heavier chronic disease.The data of the publication of national health State Family Planning Commission in 2016 are shown: China 18 years old and the above adult hypertension Illness rate is 25.2%.Although hypertension awareness, treatment rate, the control rate of population of China have improvement in recent years, place In reduced levels.Global disease burden is shown: Chinese population because caused by hypertension Disability adjusted life years (DALY) it is high Up to 37,940,000 man-years, the 12.0% of the total DALY of Zhan, account for the 63.5% of the total DALY of cardiovascular disease;Wherein disability Years of life lost It (YLD) is 35,570,000 man-years, early death Years of life lost (YLL) is 236.5 ten thousand man-years, accounts for cardiovascular disease YLD and YLL 50.1% and 64.5%, it is the first risk factor of cardiovascular disease burden.The whole nation every year because blood pressure increase caused by premature death Number is up to more than 200 ten thousand, and annual direct medical cost is up to 36,600,000,000, the reach mark blood pressure rate of the hypertensive patient after China's treatment 29.6%.For hypertension as the most important risk factor of cardiovascular and cerebrovascular diseases, epidemic status is serious, major complications such as stroke, The lethality height of disabling of myocardial infarction, heart failure and chronic kidney disease etc., serious consumption medical treatment and social resources, to family and Society causes heavy burden, it has also become the important public health problem in one, China.Although the diagnosis of hypertension in recent years and controlling Treatment makes significant progress, and hypertension therapeutic drug also emerges one after another, but condition of medicine treatment for hypertension also exist it is many it is unreasonable it Thus place also affects compliance, duration and the controlling of blood pressure rate of patient's treatment.
The individual difference of drug response is the principal element that clinically current controlling of blood pressure rate is low, generates this species diversity Reason has very much, for example many factors including raising, gene, gender, weight, disease condition can lead to Different Individual for medicine The difference of the reaction of object, however inherent cause is wherein the most fundamental factor, the metabolism of drug, transhipment, receptor gene polymorphic Property directly determine its coding protein function difference, thus be drug metabolism absorb generate difference, lead to people's blood concentration It is dramatically different.Current clinically common 5 major class drug and corresponding oligogene polymorphism and function effect (table as follows 1):
Table 1: the clinical meaning of hypertension drug associated genotype
Above-described gene mutation have it is larger may be related to reaction of the hypertension drug in Different Individual, it is identical The drug of dosage generates notable difference in Different Individual, and effectively, some individuals are absolutely void or even somebody produces for some individuals Raw drug response.Therefore, genetic test is carried out for hypertensive patient using effectively genetic polymorphism detection technology, according to inspection The types of medicines or dosage for surveying the adjustable patient of result, can make drug play the best use, while can prevent drug Toxic side effect.This provides optimal scientific practice argument for Personalized medicine in precisely medical treatment, to meet wider individuation The arriving in medical epoch keeps punching.
Have much for the technology of genetic polymorphism detection at present, it is most common to have polymerase chain reaction-restricted The technologies such as segment length polymorphism analysis (PCR-RFLP method), sequence-specific PCR, generation sequencing, the sequencing of two generations, but these skills Art has respective applied defect, and what is had is cumbersome, and detection cycle is long, can not carry out high-throughput multidigit point while detect, so that It is clinically still undesirable for polymorphism detection technique application at present, it is unable to satisfy clinical detection demand always.
Multiple fluorescence PCR combination high-resolution sonde method melting curve method is a kind of novel snp analysis technology, is from HRM It is improved on the basis of (high-resolution solubility curve) technology, the saturable dye in HRM is substituted with probe, and probe is set The position of meter just in SNP site, keeps testing result more direct, and more specifically, and maximum advantage is can to carry out parting Detection, a probe distinguish all polymorphic implementations of a SNP site, detect in conjunction with multicolor fluorescence, make to detect flux significantly It is promoted, and one fluorescence channel of conventional fluorescent PCR method can only detect a kind of genotype, if using sonde method melting curve method one A fluorescence channel can detecte 3 kinds of genotype or even can be more, and flux is made to amplify 3 times, and what it is with greater need for explanation is using conventional Fluorescence PCR method faces the interference between hypotype, so that the method that interpretation majority uses Ct value difference, makes testing result become unstable It is fixed.
(3) summary of the invention
In order to overcome the deficiencies of the prior art, the object of the present invention is to provide hypertension individuation medication guide genetic tests Kit and its application, including detect respectively CYP2C9*3 gene, CYP2D6 gene, CYP3A5*3 gene, ADRB1 gene, The reagent of AGTR1 gene, ACE gene and NPPA gene pleiomorphism.
A kind of shr gene polymorphism fluorescent PCR solubility curve detection kit, it is main include three groups of primer pairs and PCR reaction reagent, which is characterized in that the primer sequence is as follows:
Primed probe group one is CYP3A5*3 and NPPA primer:
CYP3A5*3 primer probe sequence is as follows:
Upstream primer: 5 '-TAATGAAGTATTTTAAACATATA-3 '
Downstream primer: 5 '-GTTCTAGTTCATTAGGGTGTGACAC-3 '
Fluorescence probe: FAM-TTTGTCTTTCAATATCTC-BQ1;
NPPA primer probe sequence is as follows:
Upstream primer: 5 '-GATGGGATGATCACAAC-3 '
Downstream primer: 5 '-CCAGGTCACCAAGCCAGATA-3 '
Fluorescence probe: HEX-TGTTATCTTCAGTAC-BQ2;
Primed probe group two is AGTR1, CYP2C9*3 and ACE (I/D) primer:
AGTR1 primer probe sequence is as follows:
Upstream primer: 5 '-TTCTAAAATATATTCCCC-3 '
Downstream primer: 5 '-GAAAAGTCGGTTCAGTCCACATAAT-3 '
Fluorescence probe: FAM-CCAAATGAGCATTAGCT-BQ1;
CYP2C9*3 primer probe sequence is as follows:
Upstream primer: 5 '-AGAGATTGAACGTGTGATTGGCA-3 '
Downstream primer: 5 '-TGATACTATGAATTTGGGGACTTCG-3 '
Fluorescence probe: HEX-GAGATACATTGACC-BQ2;
ACE (I/D) primer probe sequence is as follows:
Upstream primer: 5 '-TCCCATCCTTTCTCCCATTTCTCTA-3 '
Downstream primer: 5 '-CCCTTAGCTCACCTCTGCTTGTA-3 '
Fluorescence probe: CY5-GCTGCCTATACAGTCACT-BQ2;
Primed probe group three is ADRB1 and CYP2D6*10 primer:
ADRB1 primer probe sequence is as follows:
Upstream primer: 5 '-CCCATCATCTACTGCCGCAGC-3 '
Downstream primer: 5 '-TCTCCGTGGGTCGCGTG-3 '
Fluorescence probe: FAM-CTTCCAGGGACTGCTCT-BQ1;
CYP2D6*10 primer probe sequence is as follows:
Upstream primer: 5 '-CCCATTTGGTAGTGAGGCAGGT-3 '
Downstream primer: 5 '-GACCTGATGCACCGGCG-3 '
Fluorescence probe: HEX-GCACGCTACCCACCAGG-BQ2.
When specific detection, PCR reaction solution 1 is prepared with primed probe group one and PCR reaction reagent, with two He of primed probe group PCR reaction reagent prepares PCR reaction solution 2, prepares PCR reaction solution 3 with primed probe group three and PCR reaction reagent, passes through 3 Reaction solution detects the results of 7 gene pleiomorphisms respectively.Each reaction solution includes at least two fluorescence channel, detects equipotential base Because of type, to instruct clinical application.
What above-mentioned primer specifically detected is the site rs1057910, the CYP2D6 gene of CYP2C9*3 gene The site rs1065852, the site rs776746 of CYP3A5*3 gene, the site rs1801253 of ADRB1 gene, AGTR1 gene The site rs5186, ACE gene the site rs4646994 and NPPA gene the site rs5065 polymorphism.
Reaction solution 1 include thermal starting polymerase, PCR buffer, dNTPs, CYP3A5*3 primer, CYP3A5*3 probe, NPPA primer, NPPA probe.
Reaction solution 2 includes: thermal starting polymerase, PCR buffer, dNTPs, AGTR1 primer, AGTR1 probe, CYP2C9*3 Primer, CYP2C9*3 probe, ACE (I/D) primer, ACE (I/D) probe.
Reaction solution 3 includes: thermal starting polymerase, PCR buffer, dNTPs, ADRB1 primer, ADRB1 probe, CYP2D6* 10 primers, CYP2D6*10 probe.
The kit also typically includes 7 gene pleiomorphism plasmid standards as positive control, the standard items sequence It arranges as follows:
CYP3A5*3 standard items sequence:
CYP3A5*3 saltant type:
5’-CTTTTTGATAATGAAGTATTTTAAACATATAAAACATTATGGAGAGTGGCA TAGGAGATACCCA CGTATGTACCACCCAGCTTAACGAATGCTCTACTGTCATTTC TAACCATAATCTCTTTAAAGAGCTCTTTTGTCT TTCAGTATCTCTTCCCTGTTTGG ACCACATTACCCTTCATCATATGAAGCCTTGGGTGGCTCCTGTGTGAGACTC TTG CTGTGTGTCACACCCTAATGAACTAGAACCTAAGGTTGCTGTGTGTCGTACAACT AGGGGTAT-3';
CYP3A5*3 wild type:
5’-CTTTTTGATAATGAAGTATTTTAAACATATAAAACATTATGGAGAGTGGCA TAGGAGATACCCA CGTATGTACCACCCAGCTTAACGAATGCTCTACTGTCATTTC TAACCATAATCTCTTTAAAGAGCTCTTTTGTCT TTCAATATCTCTTCCCTGTTTGG ACCACATTACCCTTCATCATATGAAGCCTTGGGTGGCTCCTGTGTGAGACTC TTG CTGTGTGTCACACCCTAATGAACTAGAACCTAAGGTTGCTGTGTGTCGTACAACT AGGGGTAT-3';
NPPA standard items sequence:
NPPA saltant type:
5’-GCTTAGATGGGATGATCACAACTCCATGGCAACAAGATGACACAAATGC AGCAGAGACCCCAGG GGACAGGAGCCTCTTGCAGTCTGTCCCTAGGCCCAGCC CTGCTTGTCCTCCCTGGCTGTTATCTTCGGTACTGCA AAGAGAACACAGACATAT CTGGCTTGGTGACCTGGCTGTCCTGGAAAAGTCAGCTTCATGTATGAGTGTGCC CA TCCTCTGAACTTGATTACTGACCACCTGCTTCCCACCGGCCCCCACCCCAGCC TGATGACCCTCTGA-3';
NPPA wild type:
5’-GCTTAGATGGGATGATCACAACTCCATGGCAACAAGATGACACAAATGC AGCAGAGACCCCAGG GGACAGGAGCCTCTTGCAGTCTGTCCCTAGGCCCAGCC CTGCTTGTCCTCCCTGGCTGTTATCTTCAGTACTGCA AAGAGAACACAGACATAT CTGGCTTGGTGACCTGGCTGTCCTGGAAAAGTCAGCTTCATGTATGAGTGTGCC CA TCCTCTGAACTTGATTACTGACCACCTGCTTCCCACCGGCCCCCACCCCAGCC TGATGACCCTCTGA-3';
AGTR1 standard items sequence:
AGTR1 saltant type:
5’-CTCCAGCTTCTAAAATATATTCCCCCAAAAGCCAAATCCCACTCAAACCT TTCAACAAAAATGA GCACGCTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCC ACCAAGAAGCCTGCACCATGTTTTGAGGTTGAGT GACATGTTCGAAACCTGTCC ATAAAGTAATTTTGTGAAAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCA CTACCAAATGAGCCTTAGCTACTTTTCAGAATTGAAGGAGAAAATGCATTATGTG GACTGAACCGACTTTTCTAA AGCTCTGAACAAAAGCTTTTCTTTCCTTTTGCAA CAAGACAAAGCAAAGCCACATTTTGCATTAGACAGATGACG GCTGCTCGAAGA ACAATGTCAGAAACTCGATGAATGTGTTGATTTGAGAAATTTTACTGACAGAAAT GCAATCTCCCTAGCCTGCTT-3';
AGTR1 wild type:
5’-CTCCAGCTTCTAAAATATATTCCCCCAAAAGCCAAATCCCACTCAAACCT TTCAACAAAAATGA GCACGCTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCC ACCAAGAAGCCTGCACCATGTTTTGAGGTTGAGT GACATGTTCGAAACCTGTCC ATAAAGTAATTTTGTGAAAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCA CTACCAAATGAGCATTAGCTACTTTTCAGAATTGAAGGAGAAAATGCATTATGTG GACTGAACCGACTTTTCTAA AGCTCTGAACAAAAGCTTTTCTTTCCTTTTGCAA CAAGACAAAGCAAAGCCACATTTTGCATTAGACAGATGACG GCTGCTCGAAGA ACAATGTCAGAAACTCGATGAATGTGTTGATTTGAGAAATTTTACTGACAGAAAT GCAATCTCCCTAGCCTGCTT-3';
CYP2C9*3 standard items sequence:
CYP2C9*3 saltant type:
5’-TCTCCTTTTCCATCAGTTTTTACTTGTGTCTTATCAGCTAAAGTCCAGGA AGAGATTGAACGTG TGATTGGCAGAAACCGGAGCCCCTGCATGCAAGACAGGA GCCACATGCCCTACACAGATGCTGTGGTGCACGAGG TCCAGAGATACCTTGACC TTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTA T CTCATTCCCAAGGTAAGTTTGTTTCTCCTACACTGCAACTCCATGTTTTCGAAG TCCCCAAATTCATAGTATCAT TTTTAAACCTCT-3';
CYP2C9*3 wild type:
5’-AGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAAGA CAGGAGCCACATGCCC TACACAGATGCTGTGGTGCACGAGGTCCAGAGATACAT TGACCTTCTCCCCACCAGCCTGCCCCATGCAGTGACC TGTGACATTAAATTCAG AAACTATCTCATTCCCAAGGTAAGTTTGTTTCTCCTACACTGCAACTCCATGTTTT C GAAGTCCCCAAATTCATAGTATCATTTTTAAACCTCT-3’
ACE (I/D) standard items sequence:
ACE-D plasmid:
5’-AGACTCAAGCACGCCCCTCACAGGACTGCTGAGGCCCTGCAGGTGTCT GCAGCATGTGGCCCCA GGCCGGGGACTCTGTAAGCCACTGCTGGAGAGCCACT CCCATCCTTTCTCCCATTTCTCTAGACCTGCTGCCTAT ACAGTCACTTTTATGTGG TTTCGCCAATTTTATTCCAGCTCTGAAATTCTCTGAGCTCCCCTTACAAGCAGAG G TGAGCTAAGGGCTGGAGCTCAAGGCATTCAAACCCCTACCAGATCTGACGAAT GTGATGGCCACGTCCCGGAAAT ATGAAGACCTGTTATGGGCATGGGAGGGCTGG CGAGACAAGGCGGGGAGAGCCATCCTCCAGTTTTACCCGAAAT ACGTGGAACT CATCAACCAGGCTGCCCGGCTCAATG-3';
ACE-I plasmid:
5’-AGACTCAAGCACGCCCCTCACAGGACTGCTGAGGCCCTGCAGGTGTCT GCAGCATGTGGCCCCA GGCCGGGGACTCTGTAAGCCACTGCTGGAGAGCCACT CCCATCCTTTCTCCCATTTCTCTAGACCTGCTGCCTAT ACAGTCACTTTTTTTTTTT TTTTGAGACGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCGGGATCT C GGCTCACTGCAAGCTCCGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCT CCCAAGTAGCTGGGACCACAGG CGCCCGCCACTACGCCCGGCTAATTTTTTGTA TTTTTAGTAGAGACGGGGTTTCACCGTTTTAGCCGGGATGGTC TCGATCTCCTGA CCTCGTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGATA CAGTCACT TTTATGTGGTTTCGCCAATTTTATTCCAGCTCTGAAATTCTCTGAGCT CCCCTTACAAGCAGAGGTGAGCTAAGG GCTGGAGCTCAAGGCATTCAAACCCC TACCAGATCTGACGAATGTGATGGCCACGTCCCGGAAATATGAAGACCT GTTATG GGCATGGGAGGGCTGGCGAGACAAGGCGGGGAGAGCCATCCTCCAGTTTTACC CGAAATACGTGGAAC TCATCAACCAGGCTGCCCGGCTCAATG-3';
ADRB1 standard items sequence:
ADRB1 saltant type:
5’-ATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTCTTCCTGGCCAACGTGG TGAAGGCCTTCCACC GCGAGCTGGTGCCCGACCGCCTCTTCGTCTTCTTCAACT GGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCA TCTACTGCCGCAGCCCCG ACTTCCGCAAGGCCTTCCAGCGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCC GG CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGG CCCGGACCCCCGCCATCGCCCGGG GCCGCCTCGGACGACGACGACGACGATGT CGTCGGGGCCACGCCGCCCGCGCGCCTGCTGGAGCCCTGGGCCGGC TGCAACG GCGGGGCGGCGGC-3';
ADRB1 wild type:
5’-ATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTCTTCCTGGCCAACGTGG TGAAGGCCTTCCACC GCGAGCTGGTGCCCGACCGCCTCTTCGTCTTCTTCAACT GGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCA TCTACTGCCGCAGCCCCG ACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGC CGG CGCCACGCGACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCG GCCCGGACCCCCGCCATCGCCCGGG GCCGCCTCGGACGACGACGACGACGATG TCGTCGGGGCCACGCCGCCCGCGCGCCTGCTGGAGCCCTGGGCCGGC TGCAAC GGCGGGGCGGCGGC-3';
CYP2D6*10 standard items sequence:
CYP2D6*10 saltant type:
5’-GTGCTGAGAGTGTCCTGCCTGGTCCTCTGTGCCTGGTGGGGTGGGGGT GCCAGGTGTGTCCAGA GGAGCCCATTTGGTAGTGAGGCAGGTATGGGGCTAGA AGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCC TGCTCCTGGTGGACCT GATGCACCGGCGCCAACGCTGGGCTGCACGCTACTCACCAGGCCCCCTGCCACT GCCC GGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTT CGACCAGGTGAGGGAGGAGGTCCTG GAGGGCGGCAGAGGTGCTGAGGCTCCC CTACCAGAAGCAAACATGGATGGTGGGTGAAACCACAGGCTGGACCAG AAGCC AGGCTGAGAAGGGGA-3';
CYP2D6*10 wild type:
5’-GTGCTGAGAGTGTCCTGCCTGGTCCTCTGTGCCTGGTGGGGTGGGGGT GCCAGGTGTGTCCAGA GGAGCCCATTTGGTAGTGAGGCAGGTATGGGGCTAGA AGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCC TGCTCCTGGTGGACCT GATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCAC TGCCC GGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCT TCGACCAGGTGAGGGAGGAGGTCCTG GAGGGCGGCAGAGGTGCTGAGGCTCC CCTACCAGAAGCAAACATGGATGGTGGGTGAAACCACAGGCTGGACCAG AAGC CAGGCTGAGAAGGGGA-3’。
The invention further relates to application of the kit in detection hypertension medication gene.
The invention further relates to a kind of multiplex PCR melting curve detections using mentioned reagent box detection hypertension medication gene Method, the method are as follows:
(1) clinical blood sample is acquired, is directly used after being diluted by Sample dilution, extension rate is between 5-40 times;
(2) PCR reaction solution 1 is prepared with primed probe group one and PCR reaction reagent, is reacted with primed probe group two and PCR Preparation of reagents PCR reaction solution 2 prepares PCR reaction solution 3 with primed probe group three and PCR reaction reagent, and the blood sample after dilution is Template is directly added separately to PCR reaction solution 1, PCR reaction solution 2, in PCR reaction solution 3, and amplification cumulative volume is 20 microlitres, wherein Sample volume is 2 microlitres;
(3) PCR amplification program is set and melts program;
(4) result interpretation corresponds to different polymorphic sites by different Tm value melting peakss and directly carries out interpretation.
The Sample dilution is one of following:
(1) sodium hydroxide solution, concentration 0.01M~0.1M;
(2) DMSO, sodium hydroxide solution, wherein DMSO solution concentration is 1%~10%, concentration of sodium hydroxide solution 0.01M~0.1M;
(3) glycine betaine, sodium hydroxide solution, wherein beet alkali concentration is 1M~5M, concentration of sodium hydroxide solution 0.01M ~0.1M;
(4) mannitol, sodium hydroxide solution, wherein mannitol concentration is 1%~5%, concentration of sodium hydroxide solution 0.01M~0.1M.
The PCR reaction solution composition is as follows:
PCR reaction solution 1:Tris (PH8.5) 20mmol/L, KCL 50mmol/L, MgCL2 2mmol/L、 dNTPs 2mmol/L, polymerase 1U, CYP3A5*3 upstream primer 250nmol/L, CYP3A5*3 downstream primer 50nmol/L, CYP3A5*3 Fluorescence probe 100nmol/L, NPPA upstream primer 250nmol/L, NPPA downstream primer 50nmol/L, NPPA fluorescence probe 100nmol/L;
PCR reaction solution 2:Tris (PH8.5) 20mmol/L, KCL 50mmol/L, MgCL2 2mmol/L、 dNTPs 2mmol/L, polymerase 1U, CYP2C9 upstream primer 100nmol/L, CYP2C9 downstream primer 500nmol/L, CYP2C9 fluorescence Probe 500nmol/L, AGTR1 upstream primer 100nmol/L, AGTR1 downstream primer 500nmol/L, AGTR1 fluorescence probe 500nmol/L, ACE upstream primer 100nmol/L, ACE downstream primer 500nmol/L, ACE fluorescence probe 500nmol/L;
PCR reaction solution 3:Tris (PH8.5) 20mmol/L, KCL 50mmol/L, MgCL2 2mmol/L、 dNTPs 2mmol/L, polymerase 1U, DMSO 2%, ADRB1 upstream primer 100nmol/L, ADRB1 downstream primer 500nmol/L, ADRB1 fluorescence probe 500nmol/L, CYP2D6 upstream primer 100nmol/L, CYP2D6 downstream primer 500nmol/L, CYP2D6 fluorescence probe 500nmol/L.
The present invention is different by the Tm value difference that the difference of different bases generates, and can easily distinguish very much different mutation types.From The present invention can be seen that 7 kinds of genes in total and be related to 21 hypotypes, and the present invention is easily accomplished detection process by 3 reaction tubes, Detection process is not necessarily to nucleic acid extraction process simultaneously, simplifies operating procedure, and interpretation method is simple.
The beneficial effects are mainly reflected as follows:
1) simple and quick, it is not necessarily to nucleic acid purification process, saves the time.
2) high sensitivity can detect the nucleic acid down to 0.5ng.
3) one-time detection flux is big: not only covering 21 kinds of hypotypes of 7 allele, and required reaction liquid pipe number is few.
4) interpretation is intuitive: different subtype, instrument automatic interpretation can be distinguished according to the difference of Tm value.
(4) Detailed description of the invention
Fig. 1 is 1# sample results figure;
Fig. 2 is 2# sample results figure;
Fig. 3 is 3# sample results figure;
Fig. 4 is 4# sample results figure;
Fig. 5 is 6# sample results figure
(5) specific embodiment
The present invention is described further combined with specific embodiments below, but protection scope of the present invention is not limited in This:
Embodiment 1:
1. reaction solution is prepared
1) reaction solution 1 is prepared
Take 2 milliliters of cryopreservation tubes, be separately added into 200 μ l of Tris (PH8.5) of 0.2mol/L, 200 μ l of KCL of 0.5mol/L, The MgCL of 20mmol/L2200 μ l, 40 μ l of dNTPs of 100mmol/L, polymerase 100U, 100 μM of the upstream CYP3A5*3 are drawn 5 μ l of object, 100 μM of 1 μ l of CYP3A5*3 downstream primer, 100 μM of 2 μ l of CYP3A5*3 fluorescence probe, 100 μM of the upstream NPPA 5 μ l of primer, 100 μM of 1 μ l of NPPA downstream primer, 100 μM of 2 μ l of NPPA fluorescence probe.Volume is supplied to 1.8ml with purified water, It is spare to mix well rear stored frozen.
2) reaction solution 2 is prepared
Take 2 milliliters of cryopreservation tubes, be separately added into 200 μ l of Tris (PH8.5) of 0.2mol/L, 200 μ l of KCL of 0.5mol/L, The MgCL of 20mmol/L2200 μ l, 40 μ l of dNTPs of 100mmol/L, polymerase 100U, 100 μM of CYP2C9 upstream primer 2 μ l, 100 μM of 10 μ l of CYP2C9 downstream primer, 100 μM of 10 μ l of CYP2C9 fluorescence probe, 100 μM of AGTR1 upstream primer 2 μ l, 100 μM of 10 μ l of AGTR1 downstream primer, 100 μM of 10 μ l of AGTR1 fluorescence probe, 100 μM of 2 μ l of ACE upstream primer, 100 μM of 10 μ l of ACE downstream primer, 100 μM of 1 μ l of ACE fluorescence probe.Volume is supplied to 1.8ml with purified water, is mixed well Stored frozen is spare afterwards.
3) reaction solution 3 is prepared
Take 2 milliliters of cryopreservation tubes, be separately added into 200 μ l of Tris (PH8.5) of 0.2mol/L, 200 μ l of KCL of 0.5mol/L, The MgCL of 20mmol/L2200 μ l, 40 μ l of dNTPs of 100mmol/L, polymerase 100U, 100 μM of ADRB1 upstream primer 2.5 μ l, 100 μM of 15 μ l of ADRB1 downstream primer, 100 μM of 10 μ l of ADRB1 fluorescence probe, 100 μM of the upstream CYP2D6 are drawn 2 μ l of object, 100 μM of 10 μ l of CYP2D6 downstream primer, 100 μM of 10 μ l of CYP2D6 fluorescence probe.Volume is supplied extremely with purified water It is spare to mix well rear stored frozen by 1.8ml.
4) Sample dilution is prepared
Sodium hydroxide solution is prepared, concentration 0.04M is divided in 2 milliliters of cryopreservation tubes, and room temperature preservation is spare.
5) negative controls are prepared
Using purified water, it is divided in 2 milliliters of cryopreservation tubes according to 0.5ml, room temperature preservation is spare.
6) positive reference substance is prepared
Take 2 milliliters of cryopreservation tubes, be separately added into 10 6 power concentration CYP2D6*10, CYP2C9*3, ADRB1 (1165G > C), AGTR1 (1166A > C), CYP3A5*3, NPPA (T2238C), ACE (I/D) plasmid, each gene include wild type and dash forward Modification.It is spare to mix well rear stored frozen.
2. Sample pretreatment
10 μ l whole blood samples (room temperature is melted and mixed well) are taken, 290 μ l Sample dilutions is added, mixes well standby With extraction product can also be used.
3. sample-adding
Single reaction total volume is 20 μ l, therefore is divided in order into the PCR thin-wall tube that above-mentioned packing has 18 μ l reaction solutions 2 μ l positive controls, 2 μ l negative controls, 2 μ l specimen samples are not added, 8 union pipe lids are covered tightly, after then mixing gently 8 unions Micro- centrifugation is finally transferred to PCR detection zone.Sample-adding can refer to 96 orifice plate suggestions layout (table 2).
96 orifice plate suggestion of table 2:PCR instrument layout
4.PCR amplification and fluorescence detection
Cycling condition setting is as follows
Table 3: response procedures
Instrument channel selects: reaction solution 1 and reaction solution 3 are FAM and HEX, and reaction solution 2 is FAM/HEX/CY5.
5. interpretation of result
1) negative control should may be contaminated or operate for reagent without obvious melting peakss, if there are melting peakss after analysis Pollution in the process is detected again behind the source that please decontaminate.
2) positive control after melting curve analysis should every each channel of pipe have 2 melting peakss, if positive control pipe without Only there is 1 melting peaks in melting peakss, and whether still before the deadline reagent used in PLSCONFM, determines whether operation strictly presses Book carries out as directed.
3) sample interpretation method carries out interpretation according to following table standard
Table 4: target gene and positive control melt Tm value range
According to testing result, the corresponding different melting peakss in different channels, represent different hypotypes.
Embodiment 2:
1. reagent susceptibility test
1) experiment sample, each gene hypotype clinical sample, extraction product dilution to kit minimum detection limit 0.5ng, Retest 3 times, negative or positive findings are judged by last liquation.
2) loading is tested
2 μ l of susceptibility sample, each sample retest 3 times are separately added into reaction solution 1, reaction solution 2, reaction solution 3 Post analysis result.
3) testing result
Three reaction solution detection sensitivity sample results are the positive, and reproducible results is consistent.
Table 5: susceptibility pattern detection result
2. specific test sample
1) experiment sample is verified using specificity of the specific sample to reagent, wherein 2 parts are Escherichia coli, 2 Part be BCG vaccine, 2 parts be soybean genome.
2) loading is tested
Specific 2 μ l of sample is separately added into reaction solution 1, reaction solution 2, reaction solution 3, while it is right that the negative and positive is arranged According to product, 1 post analysis result of each sample retest.
3) testing result
It is feminine gender that three reaction solutions, which detect specific sample results, illustrates that kit specificity is functional.
Table 6: specific pattern detection result
Susceptibility sample Reaction solution 1 Reaction solution 2 Reaction solution 3
Escherichia coli 1 It is negative It is negative It is negative
Escherichia coli 2 It is negative It is negative It is negative
BCG vaccine 1 It is negative It is negative It is negative
BCG vaccine 2 It is negative It is negative It is negative
Soybean gene 1 It is negative It is negative It is negative
Soybean gene 2 It is negative It is negative It is negative
Embodiment 3: detection clinical sample 20
1) experiment sample, clinical sample derives from Chifeng hospital, by Sample dilution in kit, according to 20 samples are carried out pre-treatment by method in embodiment 1.
2) loading is tested
2 μ l of clinical sample after being separately added into dilution in reaction solution 1, reaction solution 2, reaction solution 3, each sample repeat to survey Try 1 post analysis result.
3) testing result
Three reaction solution detection sensitivity sample results are the positive, and testing result is as follows:
Table 7: clinical sample testing result
The method of the present invention that the above embodiments are only used to help understand and its core concept.It should be pointed out that for For those skilled in the art, without departing from the principle of the present invention, if can also be carried out to the present invention Dry improvement and modification, these improvement and modification are also fallen into the claims in the present invention protection scope.

Claims (6)

1. a kind of shr gene polymorphism fluorescent PCR solubility curve detection kit mainly includes three groups of primer pairs and PCR anti- Answer reagent, which is characterized in that the primer sequence is as follows:
Primed probe group one is CYP3A5*3 and NPPA primer:
CYP3A5*3 primer probe sequence is as follows:
Upstream primer: 5 '-TAATGAAGTATTTTAAACATATA-3 '
Downstream primer: 5 '-GTTCTAGTTCATTAGGGTGTGACAC-3 '
Fluorescence probe: FAM-TTTGTCTTTCAATATCTC-BQ1;
NPPA primer probe sequence is as follows:
Upstream primer: 5 '-GATGGGATGATCACAAC-3 '
Downstream primer: 5 '-CCAGGTCACCAAGCCAGATA-3 '
Fluorescence probe: HEX-TGTTATCTTCAGTAC-BQ2;
Primed probe group two is AGTR1, CYP2C9*3 and ACE (I/D) primer:
AGTR1 primer probe sequence is as follows:
Upstream primer: 5 '-TTCTAAAATATATTCCCC-3 '
Downstream primer: 5 '-GAAAAGTCGGTTCAGTCCACATAAT-3 '
Fluorescence probe: FAM-CCAAATGAGCATTAGCT-BQ1;
CYP2C9*3 primer probe sequence is as follows:
Upstream primer: 5 '-AGAGATTGAACGTGTGATTGGCA-3 '
Downstream primer: 5 '-TGATACTATGAATTTGGGGACTTCG-3 '
Fluorescence probe: HEX-GAGATACATTGACC-BQ2;
ACE (I/D) primer probe sequence is as follows:
Upstream primer: 5 '-TCCCATCCTTTCTCCCATTTCTCTA-3 '
Downstream primer: 5 '-CCCTTAGCTCACCTCTGCTTGTA-3 '
Fluorescence probe: CY5-GCTGCCTATACAGTCACT-BQ2;
Primed probe group three is ADRB1 and CYP2D6*10 primer:
ADRB1 primer probe sequence is as follows:
Upstream primer: 5 '-CCCATCATCTACTGCCGCAGC-3 '
Downstream primer: 5 '-TCTCCGTGGGTCGCGTG-3 '
Fluorescence probe: FAM-CTTCCAGGGACTGCTCT-BQ1;
CYP2D6*10 primer probe sequence is as follows:
Upstream primer: 5 '-CCCATTTGGTAGTGAGGCAGGT-3 '
Downstream primer: 5 '-GACCTGATGCACCGGCG-3 '
Fluorescence probe: HEX-GCACGCTACCCACCAGG-BQ2.
2. kit as described in claim 1, it is characterised in that the kit further includes 7 gene pleiomorphism plasmid controls Product, the standard items sequence are as follows:
CYP3A5*3 standard items sequence:
CYP3A5*3 saltant type:
5’-CTTTTTGATAATGAAGTATTTTAAACATATAAAACATTATGGAGAGTGGCATAGGAGATACCCACGTAT GTACCACCCAGCTTAACGAATGCTCTACTGTCATTTCTAACCATAATCTCTTTAAAGAGCTCTTTTGTCTTTCAGT ATCTCTTCCCTGTTTGGACCACATTACCCTTCATCATATGAAGCCTTGGGTGGCTCCTGTGTGAGACTCTTGCTGT GTGTCACACCCTAATGAACTAGAACCTAAGGTTGCTGTGTGTCGTACAACTAGGGGTAT-3';
CYP3A5*3 wild type:
5’-CTTTTTGATAATGAAGTATTTTAAACATATAAAACATTATGGAGAGTGGCATAGGAGATACCCACGTAT GTACCACCCAGCTTAACGAATGCTCTACTGTCATTTCTAACCATAATCTCTTTAAAGAGCTCTTTTGTCTTTCAAT ATCTCTTCCCTGTTTGGACCACATTACCCTTCATCATATGAAGCCTTGGGTGGCTCCTGTGTGAGACTCTTGCTGT GTGTCACACCCTAATGAACTAGAACCTAAGGTTGCTGTGTGTCGTACAACTAGGGGTAT-3';
NPPA standard items sequence:
NPPA saltant type:
5’-GCTTAGATGGGATGATCACAACTCCATGGCAACAAGATGACACAAATGCAGCAGAGACCCCAGGGGACA GGAGCCTCTTGCAGTCTGTCCCTAGGCCCAGCCCTGCTTGTCCTCCCTGGCTGTTATCTTCGGTACTGCAAAGAGA ACACAGACATATCTGGCTTGGTGACCTGGCTGTCCTGGAAAAGTCAGCTTCATGTATGAGTGTGCCCATCCTCTGA ACTTGATTACTGACCACCTGCTTCCCACCGGCCCCCACCCCAGCCTGATGACCCTCTGA-3';
NPPA wild type:
5’-GCTTAGATGGGATGATCACAACTCCATGGCAACAAGATGACACAAATGCAGCAGAGACCCCAGGGGACA GGAGCCTCTTGCAGTCTGTCCCTAGGCCCAGCCCTGCTTGTCCTCCCTGGCTGTTATCTTCAGTACTGCAAAGAGA ACACAGACATATCTGGCTTGGTGACCTGGCTGTCCTGGAAAAGTCAGCTTCATGTATGAGTGTGCCCATCCTCTGA ACTTGATTACTGACCACCTGCTTCCCACCGGCCCCCACCCCAGCCTGATGACCCTCTGA-3';
AGTR1 standard items sequence:
AGTR1 saltant type:
5’-CTCCAGCTTCTAAAATATATTCCCCCAAAAGCCAAATCCCACTCAAACCTTTCAACAAAAATGAGCACG CTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCCACCAAGAAGCCTGCACCATGTTTTGAGGTTGAGTGACATG TTCGAAACCTGTCCATAAAGTAATTTTGTGAAAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCACTACCAAA TGAGCCTTAGCTACTTTTCAGAATTGAAGGAGAAAATGCATTATGTGGACTGAACCGACTTTTCTAAAGCTCTGAA CAAAAGCTTTTCTTTCCTTTTGCAACAAGACAAAGCAAAGCCACATTTTGCATTAGACAGATGACGGCTGCTCGAA GAACAATGTCAGAAACTCGATGAATGTGTTGATTTGAGAAATTTTACTGACAGAAATGCAATCTCCCTAGCCTGC TT-3';
AGTR1 wild type:
5’-CTCCAGCTTCTAAAATATATTCCCCCAAAAGCCAAATCCCACTCAAACCTTTCAACAAAAATGAGCACG CTTTCCTACCGCCCCTCAGATAATGTAAGCTCATCCACCAAGAAGCCTGCACCATGTTTTGAGGTTGAGTGACATG TTCGAAACCTGTCCATAAAGTAATTTTGTGAAAGAAGGAGCAAGAGAACATTCCTCTGCAGCACTTCACTACCAAA TGAGCATTAGCTACTTTTCAGAATTGAAGGAGAAAATGCATTATGTGGACTGAACCGACTTTTCTAAAGCTCTGAA CAAAAGCTTTTCTTTCCTTTTGCAACAAGACAAAGCAAAGCCACATTTTGCATTAGACAGATGACGGCTGCTCGAA GAACAATGTCAGAAACTCGATGAATGTGTTGATTTGAGAAATTTTACTGACAGAAATGCAATCTCCCTAGCCTGC TT-3';
CYP2C9*3 standard items sequence:
CYP2C9*3 saltant type:
5’-TCTCCTTTTCCATCAGTTTTTACTTGTGTCTTATCAGCTAAAGTCCAGGAAGAGATTGAACGTGTGATT GGCAGAAACCGGAGCCCCTGCATGCAAGACAGGAGCCACATGCCCTACACAGATGCTGTGGTGCACGAGGTCCAGA GATACCTTGACCTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGACATTAAATTCAGAAACTATCTCATTCC CAAGGTAAGTTTGTTTCTCCTACACTGCAACTCCATGTTTTCGAAGTCCCCAAATTCATAGTATCATTTTTAAACC TCT-3';
CYP2C9*3 wild type:
5’-AGAGATTGAACGTGTGATTGGCAGAAACCGGAGCCCCTGCATGCAAGACAGGAGCCACATGCCCTACAC AGATGCTGTGGTGCACGAGGTCCAGAGATACATTGACCTTCTCCCCACCAGCCTGCCCCATGCAGTGACCTGTGAC ATTAAATTCAGAAACTATCTCATTCCCAAGGTAAGTTTGTTTCTCCTACACTGCAACTCCATGTTTTCGAAGTCCC CAAATTCATAGTATCATTTTTAAACCTCT-3’
ACE (I/D) standard items sequence:
ACE-D plasmid:
5’-AGACTCAAGCACGCCCCTCACAGGACTGCTGAGGCCCTGCAGGTGTCTGCAGCATGTGGCCCCAGGCCG GGGACTCTGTAAGCCACTGCTGGAGAGCCACTCCCATCCTTTCTCCCATTTCTCTAGACCTGCTGCCTATACAGTC ACTTTTATGTGGTTTCGCCAATTTTATTCCAGCTCTGAAATTCTCTGAGCTCCCCTTACAAGCAGAGGTGAGCTAA GGGCTGGAGCTCAAGGCATTCAAACCCCTACCAGATCTGACGAATGTGATGGCCACGTCCCGGAAATATGAAGACC TGTTATGGGCATGGGAGGGCTGGCGAGACAAGGCGGGGAGAGCCATCCTCCAGTTTTACCCGAAATACGTGGAACT CATCAACCAGGCTGCCCGGCTCAATG-3';
ACE-I plasmid:
5’-AGACTCAAGCACGCCCCTCACAGGACTGCTGAGGCCCTGCAGGTGTCTGCAGCATGTGGCCCCAGGCCG GGGACTCTGTAAGCCACTGCTGGAGAGCCACTCCCATCCTTTCTCCCATTTCTCTAGACCTGCTGCCTATACAGTC ACTTTTTTTTTTTTTTTGAGACGGAGTCTCGCTCTGTCGCCCAGGCTGGAGTGCAGTGGCGGGATCTCGGCTCACT GCAAGCTCCGCCTCCCGGGTTCACGCCATTCTCCTGCCTCAGCCTCCCAAGTAGCTGGGACCACAGGCGCCCGCCA CTACGCCCGGCTAATTTTTTGTATTTTTAGTAGAGACGGGGTTTCACCGTTTTAGCCGGGATGGTCTCGATCTCCT GACCTCGTGATCCGCCCGCCTCGGCCTCCCAAAGTGCTGGGATTACAGGCGTGATACAGTCACTTTTATGTGGTTT CGCCAATTTTATTCCAGCTCTGAAATTCTCTGAGCTCCCCTTACAAGCAGAGGTGAGCTAAGGGCTGGAGCTCAAG GCATTCAAACCCCTACCAGATCTGACGAATGTGATGGCCACGTCCCGGAAATATGAAGACCTGTTATGGGCATGGG AGGGCTGGCGAGACAAGGCGGGGAGAGCCATCCTCCAGTTTTACCCGAAATACGTGGAACTCATCAACCAGGCTGC CCGGCTCAATG-3';
ADRB1 standard items sequence:
ADRB1 saltant type:
5’-ATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTCTTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAG CTGGTGCCCGACCGCCTCTTCGTCTTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACT GCCGCAGCCCCGACTTCCGCAAGGCCTTCCAGCGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGGCGCCACGC GACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCCCCGCCATCGCCCGGGGCCGCCTCG GACGACGACGACGACGATGTCGTCGGGGCCACGCCGCCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCG GGGCGGCGGC-3';
ADRB1 wild type:
5’-ATGGGCGTCTTCACGCTCTGCTGGCTGCCCTTCTTCCTGGCCAACGTGGTGAAGGCCTTCCACCGCGAG CTGGTGCCCGACCGCCTCTTCGTCTTCTTCAACTGGCTGGGCTACGCCAACTCGGCCTTCAACCCCATCATCTACT GCCGCAGCCCCGACTTCCGCAAGGCCTTCCAGGGACTGCTCTGCTGCGCGCGCAGGGCTGCCCGCCGGCGCCACGC GACCCACGGAGACCGGCCGCGCGCCTCGGGCTGTCTGGCCCGGCCCGGACCCCCGCCATCGCCCGGGGCCGCCTCG GACGACGACGACGACGATGTCGTCGGGGCCACGCCGCCCGCGCGCCTGCTGGAGCCCTGGGCCGGCTGCAACGGCG GGGCGGCGGC-3';
CYP2D6*10 standard items sequence:
CYP2D6*10 saltant type:
5’-GTGCTGAGAGTGTCCTGCCTGGTCCTCTGTGCCTGGTGGGGTGGGGGTGCCAGGTGTGTCCAGAGGAGC CCATTTGGTAGTGAGGCAGGTATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCC TGGTGGACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACTCACCAGGCCCCCTGCCACTGCCCGGGCTGGG CAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAGGTGAGGGAGGAGGTCCTGGAGGGCGGC AGAGGTGCTGAGGCTCCCCTACCAGAAGCAAACATGGATGGTGGGTGAAACCACAGGCTGGACCAGAAGCCAGGCT GAGAAGGGGA-3';
CYP2D6*10 wild type:
5’-GTGCTGAGAGTGTCCTGCCTGGTCCTCTGTGCCTGGTGGGGTGGGGGTGCCAGGTGTGTCCAGAGGAGC CCATTTGGTAGTGAGGCAGGTATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCC TGGTGGACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTGCCCGGGCTGGG CAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAGGTGAGGGAGGAGGTCCTGGAGGGCGGC AGAGGTGCTGAGGCTCCCCTACCAGAAGCAAACATGGATGGTGGGTGAAACCACAGGCTGGACCAGAAGCCAGGCT GAGAAGGGGA-3’。
3. application of the kit of any of claims 1 or 2 in detection hypertension medication gene.
4. a kind of multiplex PCR melting curve detection method using the detection hypertension medication gene of kit described in claim 1, The method is as follows:
(1) clinical blood sample is acquired, is directly used after being diluted by Sample dilution, extension rate is between 5-40 times;
(2) PCR reaction solution 1 is prepared with primed probe group one and PCR reaction reagent, with primed probe group two and PCR reaction reagent PCR reaction solution 2 is prepared, PCR reaction solution 3 is prepared with primed probe group three and PCR reaction reagent, the blood sample after dilution is that template is straight It connects and is added separately to PCR reaction solution 1, PCR reaction solution 2, in PCR reaction solution 3, amplification cumulative volume is 20 microlitres, wherein sample body Product is 2 microlitres;
(3) PCR amplification program is set and melts program;
(4) result interpretation corresponds to different polymorphic sites by different Tm value melting peakss and directly carries out interpretation.
5. method as claimed in claim 4, it is characterised in that the Sample dilution is one of following:
(1) sodium hydroxide solution, concentration 0.01M~0.1M;
(2) DMSO, sodium hydroxide solution, wherein DMSO solution concentration is 1%~10%, concentration of sodium hydroxide solution 0.01M~ 0.1M;
(3) glycine betaine, sodium hydroxide solution, wherein beet alkali concentration be 1M~5M, concentration of sodium hydroxide solution 0.01M~ 0.1M;
(4) mannitol, sodium hydroxide solution, wherein mannitol concentration is 1%~5%, concentration of sodium hydroxide solution 0.01M~ 0.1M。
6. method as claimed in claim 4, it is characterised in that the PCR reaction solution composition is as follows:
PCR reaction solution 1:Tris (PH8.5) 20mmol/L, KCL 50mmol/L, MgCL22mmol/L, dNTPs 2mmol/L, gather Synthase 1U, CYP3A5*3 upstream primer 250nmol/L, CYP3A5*3 downstream primer 50nmol/L, CYP3A5*3 fluorescence probe 100nmol/L, NPPA upstream primer 250nmol/L, NPPA downstream primer 50nmol/L, NPPA fluorescence probe 100nmol/L;
PCR reaction solution 2:Tris (PH8.5) 20mmol/L, KCL 50mmol/L, MgCL22mmol/L, dNTPs 2mmol/L, gather Synthase 1U, CYP2C9 upstream primer 100nmol/L, CYP2C9 downstream primer 500nmol/L, CYP2C9 fluorescence probe 500nmol/ L, on AGTR1 upstream primer 100nmol/L, AGTR1 downstream primer 500nmol/L, AGTR1 fluorescence probe 500nmol/L, ACE Swim primer 100nmol/L, ACE downstream primer 500nmol/L, ACE fluorescence probe 500nmol/L;
PCR reaction solution 3:Tris (PH8.5) 20mmol/L, KCL 50mmol/L, MgCL22mmol/L, dNTPs 2mmol/L, gather Synthase 1U, DMSO 2%, ADRB1 upstream primer 100nmol/L, ADRB1 downstream primer 500nmol/L, ADRB1 fluorescence probe 500nmol/L, CYP2D6 upstream primer 100nmol/L, CYP2D6 downstream primer 500nmol/L, CYP2D6 fluorescence probe 500nmol/L。
CN201810245896.8A 2018-03-23 2018-03-23 Shr gene polymorphism fluorescent PCR solubility curve detection kit and application Pending CN109457024A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810245896.8A CN109457024A (en) 2018-03-23 2018-03-23 Shr gene polymorphism fluorescent PCR solubility curve detection kit and application

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810245896.8A CN109457024A (en) 2018-03-23 2018-03-23 Shr gene polymorphism fluorescent PCR solubility curve detection kit and application

Publications (1)

Publication Number Publication Date
CN109457024A true CN109457024A (en) 2019-03-12

Family

ID=65606268

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810245896.8A Pending CN109457024A (en) 2018-03-23 2018-03-23 Shr gene polymorphism fluorescent PCR solubility curve detection kit and application

Country Status (1)

Country Link
CN (1) CN109457024A (en)

Cited By (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109929925A (en) * 2019-03-22 2019-06-25 踏石生物科技(苏州)有限公司 Using 65 site CC type of people ADBR1 gene 11 as the positive reference product of template
CN109943629A (en) * 2019-03-22 2019-06-28 踏石生物科技(苏州)有限公司 A kind of ADRB1 G1165C genotype detection kit and its detection method
CN110257506A (en) * 2019-07-09 2019-09-20 杭州千基生物科技有限公司 Polymorphism detection kit and method for hypertension accurate medication related gene
CN110863042A (en) * 2019-10-11 2020-03-06 济南和合医学检验有限公司 Method for detecting hypertension related gene by using multiple PCR technology
CN111100929A (en) * 2020-01-17 2020-05-05 郑州安图生物工程股份有限公司 Kit for detecting polymorphism of drug-related gene for hypertension
CN111334573A (en) * 2020-04-28 2020-06-26 重庆浦洛通基因医学研究院有限公司 Gene detection kit for hypertension medication and use method
CN111793676A (en) * 2020-07-21 2020-10-20 北京安智因生物技术有限公司 Method and kit for detecting gene polymorphism and application thereof
CN112695083A (en) * 2021-02-05 2021-04-23 北京核子华曦医学检验实验室有限公司 Nucleic acid composition and kit for detecting gene polymorphism of medicine for hypertension
CN114480594A (en) * 2021-12-23 2022-05-13 郑州华之源医学检验实验室有限公司 Method and kit for detecting multiple single nucleotide polymorphisms and application thereof
CN116814777A (en) * 2023-08-25 2023-09-29 北京宏微特斯生物科技有限公司 Kit for guiding related gene polymorphic sites by using hypertension and application method of kit

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4505839B2 (en) * 2004-05-18 2010-07-21 アークレイ株式会社 CYP2D6 * 4 mutation detection method and nucleic acid probe and kit therefor
CN106119363A (en) * 2016-07-01 2016-11-16 中国人民解放军第三〇九医院 SNP combination, detection method and test kit for the detection of antituberculotics hepatic injury susceptible genotype
CN106367479A (en) * 2016-08-25 2017-02-01 杭州百迈生物股份有限公司 Detection composition for guiding hypertension medication, applications of detection composition, kit and detection method
CN106755560A (en) * 2017-03-30 2017-05-31 德必碁生物科技(厦门)有限公司 A kind of multiple fluorescence PCR method detects the kit of hypertension medication gene pleiomorphism
CN107365850A (en) * 2017-08-11 2017-11-21 常州市第人民医院 The detection method of more SNPs in a kind of single tube
CN107641645A (en) * 2017-11-14 2018-01-30 北京阅微基因技术有限公司 Angiocardiopathy personalized medicine related gene polymorphism detection architecture and kit

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4505839B2 (en) * 2004-05-18 2010-07-21 アークレイ株式会社 CYP2D6 * 4 mutation detection method and nucleic acid probe and kit therefor
CN106119363A (en) * 2016-07-01 2016-11-16 中国人民解放军第三〇九医院 SNP combination, detection method and test kit for the detection of antituberculotics hepatic injury susceptible genotype
CN106367479A (en) * 2016-08-25 2017-02-01 杭州百迈生物股份有限公司 Detection composition for guiding hypertension medication, applications of detection composition, kit and detection method
CN106755560A (en) * 2017-03-30 2017-05-31 德必碁生物科技(厦门)有限公司 A kind of multiple fluorescence PCR method detects the kit of hypertension medication gene pleiomorphism
CN107365850A (en) * 2017-08-11 2017-11-21 常州市第人民医院 The detection method of more SNPs in a kind of single tube
CN107641645A (en) * 2017-11-14 2018-01-30 北京阅微基因技术有限公司 Angiocardiopathy personalized medicine related gene polymorphism detection architecture and kit

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KYUNGMYUNG LEE ET AL.: ""A new method for ABO genotyping using fluorescence melting curve analysis based on peptide nucleic acid probes"", 《LEGAL MEDICINE》 *
曹武奎等: "《中西医结合实用传染病学》", 31 January 2008, 天津科学技术出版社 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109929925A (en) * 2019-03-22 2019-06-25 踏石生物科技(苏州)有限公司 Using 65 site CC type of people ADBR1 gene 11 as the positive reference product of template
CN109943629A (en) * 2019-03-22 2019-06-28 踏石生物科技(苏州)有限公司 A kind of ADRB1 G1165C genotype detection kit and its detection method
CN110257506A (en) * 2019-07-09 2019-09-20 杭州千基生物科技有限公司 Polymorphism detection kit and method for hypertension accurate medication related gene
CN110863042A (en) * 2019-10-11 2020-03-06 济南和合医学检验有限公司 Method for detecting hypertension related gene by using multiple PCR technology
CN111100929A (en) * 2020-01-17 2020-05-05 郑州安图生物工程股份有限公司 Kit for detecting polymorphism of drug-related gene for hypertension
CN111334573A (en) * 2020-04-28 2020-06-26 重庆浦洛通基因医学研究院有限公司 Gene detection kit for hypertension medication and use method
CN111793676A (en) * 2020-07-21 2020-10-20 北京安智因生物技术有限公司 Method and kit for detecting gene polymorphism and application thereof
CN112695083A (en) * 2021-02-05 2021-04-23 北京核子华曦医学检验实验室有限公司 Nucleic acid composition and kit for detecting gene polymorphism of medicine for hypertension
CN114480594A (en) * 2021-12-23 2022-05-13 郑州华之源医学检验实验室有限公司 Method and kit for detecting multiple single nucleotide polymorphisms and application thereof
CN116814777A (en) * 2023-08-25 2023-09-29 北京宏微特斯生物科技有限公司 Kit for guiding related gene polymorphic sites by using hypertension and application method of kit
CN116814777B (en) * 2023-08-25 2023-12-12 北京宏微特斯生物科技有限公司 Kit for guiding related gene polymorphic sites by using hypertension and application method of kit

Similar Documents

Publication Publication Date Title
CN109457024A (en) Shr gene polymorphism fluorescent PCR solubility curve detection kit and application
CN103074434B (en) CYP2C19 gene polymorphyism detection kit and detection method thereof
Zou et al. Rapid, real-time chemiluminescent detection of DNA mutation based on digital microfluidics and pyrosequencing
CN104099425A (en) B-raf gene mutation detection kit
CN103667514B (en) A kind of human interleukin 2 8B gene pleiomorphism fluorescence PCR detection reagent kits
CN105018646B (en) A kind of primer, probe and the kit of detection bovine epizootic fever virus
US20100216123A1 (en) Method of detecting mutation and kit used in the same
CN107227361A (en) Primer, probe and detection kit for detecting CYP2C19 gene pleiomorphisms
CN106086192A (en) The parting detecting reagent of tacrolimus personalized medicine related gene
CN102925562B (en) Kit and method for detecting aminoglycoside drug-induced deafness-sensitive gene
CN105274190A (en) HRM method for detecting genetic polymorphism of CYP3A4*1G and MDR1C1236T
CN103215366A (en) Detection method for multi-genotyping based on isothermal signal amplification of nuclease and hairpin DNA (deoxyribonucleic acid) probe
CN103122387B (en) Rapid circulating tumor cell (CTCs) fluorescence PCR (Polymerase Chain Reaction) hypersensitivity detection kit and application thereof
CN103074435B (en) Kit for synchronously detecting related gene expression levels of 14 antineoplastic drugs and detection method of kit
CN108165629B (en) DNA point mutation quantitative detection method
CN104293932A (en) Method for detecting HLA-B * 5801 allele based on real-time fluorescence PCR
CN103103259A (en) Method, kit and primers for determining whether two predetermined loci of nucleic acid sample mutate or not
Chen et al. Smartphone-assisted fluorescence-based detection of sunrise-type smart amplification process and a 3D-printed ultraviolet light-emitting diode device for the diagnosis of tuberculosis
CN103074438B (en) Multi-gene detection kit for guiding administration of warfarin and detection method of multi-gene detection kit
CN105316401A (en) Method for measuring ABCC2 gene polymorphism
Song et al. Improvement of LATE-PCR to allow single-cell analysis by pyrosequencing
CN113249459A (en) Primer group for detecting gene group for medication guidance of schizophrenia patients, related application, corresponding kit and using method
CN103540676A (en) Kit for detecting mutations of A-G at 1555th site and C-T at 1494th site of mitochondrial gene
CN106319079A (en) Method for detecting 22q11.2 copy number deletion
CN104561336A (en) Method for detecting UGT2B7 gene polymorphism by virtue of high resolution melting curve analysis technology

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20211014

Address after: 310000 room 326, building 3, No. 88, Jiangling Road, Xixing street, Binjiang District, Hangzhou City, Zhejiang Province

Applicant after: Zhongfu Health Technology (Hangzhou) Co.,Ltd.

Address before: 310051 floor 15, building 5, No. 668, Bin'an Road, Binjiang District, Hangzhou City, Zhejiang Province

Applicant before: HANGZHOU TALEAD BIOTECHNOLOGY Co.,Ltd.

TA01 Transfer of patent application right